GLP3R (Reta)

What is GLP3R (Reta)?

Retatrutide (GLP3R) is a triple incretin receptor agonist targeting GLP-1R, GIP-R, and glucagon receptor simultaneously. Research has examined its potent effects on body weight, glucose metabolism, and lipid profiles in animal models. As a tri-agonist, it represents a distinct pharmacological profile compared to dual or single incretin agonists.

GLP3R (Reta) (Retatrutide) is supplied strictly as a reference material for in vitro and preclinical investigation. All characterization data described here is drawn from peer-reviewed literature and laboratory analysis; nothing herein constitutes a claim of clinical effect in humans.

Documented Research Areas

The following domains summarize directions explored across published studies and laboratory models. Each reflects observations reported in rodent models, in vitro systems, or the peer-reviewed record.

Mechanistic Pathway

Mechanistic steps below are hypothesized from in vitro assays and animal-model data reported in the literature. They describe biochemical interactions observed under controlled experimental conditions.

1. 1

   GLP-1R Agonism

   GLP-1 receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic satiety pathways — all well-characterized effects studied across the incretin class.

2. 2

   GIP-R Agonism

   GIP receptor co-activation enhances insulin secretion synergistically with GLP-1R and promotes adipocyte lipid storage under normal conditions. In the tri-agonist context, GIP-R activation is studied for its additive metabolic effects.

3. 3

   Glucagon Receptor Agonism

   Glucagon receptor co-activation increases hepatic glucose output and energy expenditure. In the context of simultaneous GLP-1R activation, researchers study how glucagon's catabolic effects contribute to enhanced fat mobilization.

4. 4

   Synergistic Tri-Receptor Activity

   The simultaneous activation of three complementary receptor systems produces effects studied to exceed those of dual or single agonists. Research has examined receptor cross-talk and downstream signaling integration in hepatic and hypothalamic models.

Molecular Specifications

Selected Literature

The following peer-reviewed references informed the research summaries on this page. Citations are provided for scientific context only.

1. Finan B, et al. (2015). A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine, 21(1), 27–36.
2. Coskun T, et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 36(5), 1234–1247.
3. Müller TD, et al. (2022). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130.
4. Adriaenssens AE, et al. (2019). Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metabolism, 30(5), 987–996.
5. Samms RJ, et al. (2021). Functionally distinct POMC-expressing neuron subpopulations in hypothalamus revealed by intersectional targeting. Nature Neuroscience, 24, 913–929.